Objective:To compare the efficacy between nateglinide and repaglinide in improving type 2 diabetes pancreatic β cell function.Methods:A double-blind

randomized clinical study was introduced to 46 patients with type 2 diabetes mellitus who were administrated with nateglinide or repaglinide for 12 weeks.Both in the 0 week and the 12th week concentration of the serum insulin

C-peptide and blood glucose

as well as plasma HbA 1c concentration

were measured respectively at preprandial 0 min and postprandial 30

60

120min.Homa-βindex

insulin response to glucose(IRG)and the ratio of the area under curve between insulin and glucose(AUCi/AUCg)were computed for statistical analysis.Results:Compared with 0 week

the levels of blood glucose and plasma HbA 1c all dropped in both groups with statistical significance(P<0.05)at the 12th week

while the differences between the two groups showed no significance.Homa-β index changed little after treatment in both groups.While AUCi/AUCg raised 12 weeks later with no difference between the two groups(P<0.05).As for index IRA

it increased significantly after treatment in both groups(P<0.05)

and rose higher in the group administrated with nateglinide than that with repaglinide(P<0.05).Conclusion:Nateglinide and repaglinide both can increase early insulin secretion and lower levels of blood glucose and HbA 1c.Nateglinide is likely to stimulate early insulin release more effectively than repaglinide at conventional dosage.